Merck KGaA to acquire biopharma CDMO Exelead for $780 million
The transaction is expected to close in the first quarter of 2022
The transaction is expected to close in the first quarter of 2022
Transformational partnership establishes PCI as a CDMO and broadens capabilities across drug product lifecycle
They enter into exclusive negotiations in a new drive to create a technology-driven leader for complex small molecules and ADCs of global scale
The move comes as the global biotech and biopharma CDMO market continues to surge, fueled by rising demand
The new equipment will be installed at Codis’ 400,000-square-foot Haverhill facility and is expected to be operational by 2027
Indomo’s ClearPen system combines a proprietary self-injection device and microneedle with a modernized triamcinolone acetonide formulation
The first of four planned modules at the new plant is expected to come online by summer 2026
The new LEED Gold-certified building will serve as CordenPharma Colorado’s sole tenant
Subscribe To Our Newsletter & Stay Updated